JP2026016527A5 - - Google Patents
Info
- Publication number
- JP2026016527A5 JP2026016527A5 JP2025178358A JP2025178358A JP2026016527A5 JP 2026016527 A5 JP2026016527 A5 JP 2026016527A5 JP 2025178358 A JP2025178358 A JP 2025178358A JP 2025178358 A JP2025178358 A JP 2025178358A JP 2026016527 A5 JP2026016527 A5 JP 2026016527A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- pharmaceutically acceptable
- dose
- mebidalen
- cocrystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163157966P | 2021-03-08 | 2021-03-08 | |
| US63/157,966 | 2021-03-08 | ||
| JP2023554835A JP7824310B2 (ja) | 2021-03-08 | 2022-03-08 | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
| PCT/US2022/019308 WO2022192231A1 (en) | 2021-03-08 | 2022-03-08 | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554835A Division JP7824310B2 (ja) | 2021-03-08 | 2022-03-08 | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026016527A JP2026016527A (ja) | 2026-02-03 |
| JP2026016527A5 true JP2026016527A5 (enExample) | 2026-05-14 |
Family
ID=80930548
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554835A Active JP7824310B2 (ja) | 2021-03-08 | 2022-03-08 | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
| JP2025178358A Pending JP2026016527A (ja) | 2021-03-08 | 2025-10-23 | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554835A Active JP7824310B2 (ja) | 2021-03-08 | 2022-03-08 | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299375A1 (enExample) |
| EP (1) | EP4304581A1 (enExample) |
| JP (2) | JP7824310B2 (enExample) |
| KR (1) | KR20230154967A (enExample) |
| CN (1) | CN117377470A (enExample) |
| AU (1) | AU2022234744B2 (enExample) |
| BR (1) | BR112023018175A2 (enExample) |
| CA (1) | CA3211261A1 (enExample) |
| MX (1) | MX2023010540A (enExample) |
| WO (1) | WO2022192231A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| EP4200280B1 (en) | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| CN116283804B (zh) * | 2022-11-09 | 2025-05-13 | 武汉科技大学 | 具有湿度稳定性和溶解度优势的氯氮平共晶及其制备方法 |
| CN118359538A (zh) * | 2023-04-18 | 2024-07-19 | 上海赛默罗生物科技有限公司 | 异喹啉类化合物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| EA035544B1 (ru) | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
-
2022
- 2022-03-08 US US18/549,546 patent/US20240299375A1/en active Pending
- 2022-03-08 EP EP22712201.7A patent/EP4304581A1/en active Pending
- 2022-03-08 KR KR1020237034218A patent/KR20230154967A/ko active Pending
- 2022-03-08 CA CA3211261A patent/CA3211261A1/en active Pending
- 2022-03-08 BR BR112023018175A patent/BR112023018175A2/pt unknown
- 2022-03-08 WO PCT/US2022/019308 patent/WO2022192231A1/en not_active Ceased
- 2022-03-08 AU AU2022234744A patent/AU2022234744B2/en active Active
- 2022-03-08 MX MX2023010540A patent/MX2023010540A/es unknown
- 2022-03-08 CN CN202280033173.6A patent/CN117377470A/zh active Pending
- 2022-03-08 JP JP2023554835A patent/JP7824310B2/ja active Active
-
2025
- 2025-10-23 JP JP2025178358A patent/JP2026016527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3018635C (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| BR9814378A (pt) | Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase | |
| JP2011520981A5 (enExample) | ||
| JP2011508765A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| US20080139654A1 (en) | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity | |
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| FI3746126T3 (fi) | Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi | |
| JP2023523569A5 (enExample) | ||
| JP2025166121A5 (enExample) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2024533756A5 (enExample) | ||
| JP2008509224A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| CN111556753A (zh) | 用于夜间尿频的治疗剂 | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2025517509A5 (enExample) | ||
| WO2023201390A1 (en) | Aqueous quetiapine solutions | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| JP2023521492A5 (enExample) | ||
| JP2023517130A5 (ja) | Ａｚｄ１６５６又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び／又は心筋炎の治療用組成物 | |
| WO2004017973A1 (ja) | 統合失調症治療剤 | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| BR112021015088A2 (pt) | Combinações terapêuticas e composições para o tratamento de doença inflamatória intestinal |